These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
30. LRRK2 haplotype-sharing analysis in Parkinson's disease reveals a novel p.S1761R mutation. Lorenzo-Betancor O; Samaranch L; Ezquerra M; Tolosa E; Lorenzo E; Irigoyen J; Gaig C; Pastor MA; Soto-Ortolaza AI; Ross OA; Rodríguez-Oroz MC; Valldeoriola F; Martí MJ; Luquin MR; Perez-Tur J; Burguera JA; Obeso JA; Pastor P Mov Disord; 2012 Jan; 27(1):146-51. PubMed ID: 22038903 [TBL] [Abstract][Full Text] [Related]
31. The G2019S LRRK2 mutation in Brazilian patients with Parkinson's disease: phenotype in monozygotic twins. Munhoz RP; Wakutani Y; Marras C; Teive HA; Raskin S; Werneck LC; Moreno D; Sato C; Lang AE; Rogaeva E Mov Disord; 2008 Jan; 23(2):290-4. PubMed ID: 17999435 [TBL] [Abstract][Full Text] [Related]
32. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease. Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749 [TBL] [Abstract][Full Text] [Related]
33. LRRK2: bridging the gap between sporadic and hereditary Parkinson's disease. Elbaz A Lancet Neurol; 2008 Jul; 7(7):562-4. PubMed ID: 18539536 [No Abstract] [Full Text] [Related]
34. LRRK2 gene G2019S mutation and SNPs [haplotypes] in subtypes of Parkinson's disease. Patra B; Parsian AJ; Racette BA; Zhao JH; Perlmutter JS; Parsian A Parkinsonism Relat Disord; 2009 Mar; 15(3):175-80. PubMed ID: 18752982 [TBL] [Abstract][Full Text] [Related]
35. A clinical, neuropsychological and olfactory evaluation of a large family with LRRK2 mutations. Lohmann E; Leclere L; De Anna F; Lesage S; Dubois B; Agid Y; Dürr A; Brice A; Parkinsonism Relat Disord; 2009 May; 15(4):273-6. PubMed ID: 18718805 [TBL] [Abstract][Full Text] [Related]
36. LRRK2 G2019S mutations may be increased in Puerto Ricans. Saunders-Pullman R; Cabassa J; San Luciano M; Stanley K; Raymond D; Ozelius LJ; Bressman SB Mov Disord; 2011 Aug; 26(9):1772-3. PubMed ID: 21449009 [No Abstract] [Full Text] [Related]
38. Is the G2019S LRRK2 mutation common in all southern European populations? Papapetropoulos S; Adi N; Shehadeh L; Bishopric N; Singer C; Argyriou AA; Chroni E J Clin Neurosci; 2008 Sep; 15(9):1027-30. PubMed ID: 18617409 [TBL] [Abstract][Full Text] [Related]
39. High frequency and reduced penetrance of LRRK2 G2019S mutation among Parkinson's disease patients in Cantabria (Spain). Sierra M; González-Aramburu I; Sánchez-Juan P; Sánchez-Quintana C; Polo JM; Berciano J; Combarros O; Infante J Mov Disord; 2011 Nov; 26(13):2343-6. PubMed ID: 21954089 [TBL] [Abstract][Full Text] [Related]
40. LRRK2-G2019S mutation is not associated with an increased cancer risk: a kin-cohort study. Allegra R; Tunesi S; Cilia R; Pezzoli G; Goldwurm S Mov Disord; 2014 Sep; 29(10):1325-6. PubMed ID: 25048644 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]